TrovaGene, Inc. Announces Pricing Of Public Offering Of Common Stock

SAN DIEGO, Feb. 6, 2015 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced the pricing of an underwritten public offering of 4,444,444 shares of its common stock. The gross proceeds to Trovagene from this offering are expected to be approximately $20 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene. The offering is expected to close on or about February 11, 2015, subject to customary closing conditions. Trovagene has also granted to the underwriters a 30-day option to purchase from it up to an additional 666,666 shares of its common stock.

Trovagene intends to use the net proceeds from this offering to fund its research and development activities and for working capital and other general corporate purposes.

Piper Jaffray & Co. is acting as sole book-running manager and Janney Montgomery Scott LLC, Maxim Group LLC and Cantor Fitzgerald & Co. are acting as co-managers for the offering.

A registration statement relating to these securities was previously filed with and has become effective by rule of the Securities and Exchange Commission. A preliminary prospectus supplement and the related prospectus have been filed with the SEC and are available on the SEC's website at http://www.sec.gov. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.

Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trovagene-inc-announces-pricing-of-public-offering-of-common-stock-300032108.html

SOURCE Trovagene, Inc.